Hepatitis C

All articles by Hepatitis C

Hep C’s number comes up: Can Biden’s 5-year plan eliminate the longtime scourge?
Hep C’s number comes up: Can Biden’s 5-year plan eliminate the longtime scourge?
Michelle Andrews, KFF Health News
September 20, 2023
2:05 pm

As drug prices have declined, and under pressure from advocates and public health experts, many states have eliminated some of those barriers that have made it difficult to get approved for treatment.

Infographic | The leaders of the global hepatitis-C market
Infographic | The leaders of the global hepatitis-C market
Virginia Lau
August 31, 2017
11:00 am

Despite approvals of competing products from AbbVie, Merck, and Bristol-Myers Squibb, Gilead remains the market leader.

Five things for pharma marketers to know: Friday, August 4, 2017
Five things for pharma marketers to know: Friday, August 4, 2017
Jaimy Lee
August 4, 2017
2:45 pm

AbbVie’s new HCV drug is cheaper than Gilead’s Harvoni; Lilly’s experimental migraine drugs beats placebo; Fitbit to launch smartwatch

Gilead’s educational campaign boosted HCV diagnosis rates for baby boomers
Gilead’s educational campaign boosted HCV diagnosis rates for baby boomers
Jaimy Lee
July 27, 2017
2:20 pm

An unbranded campaign encouraging baby boomers to get tested for hepatitis C helped boost screening and diagnosis numbers, which in turn upped sales of its HCV therapies.

Five things for pharma marketers to know: Monday, July 24, 2017
Five things for pharma marketers to know: Monday, July 24, 2017
Virginia Lau
July 24, 2017
2:55 pm

Samsung Bioepis launches Remicade biosimilar; WHO encourages uses of generic version of Sovaldi; nearly 20 million people with HIV on treatment

Five things for pharma marketers to know: Monday, April 10, 2017
Five things for pharma marketers to know: Monday, April 10, 2017
Virginia Lau
April 10, 2017
2:50 pm

Gilead receives approval to market Harvoni, Sovaldi to adolescents; OncoMed ends mid-stage trials for pancreatic cancer drug; researchers use facial recognition software to diagnose

Five things for pharma marketers to know: Wednesday, March 29, 2017
Five things for pharma marketers to know: Wednesday, March 29, 2017
Jaimy Lee
March 29, 2017
2:25 pm

A panel recommends the U.S. government license a hepatitis-C therapy; the FDA approves Roche MS drug; new eczema drug to cost $37,000 per year

Five things for pharma marketers to know: Tuesday, March 14, 2017
Five things for pharma marketers to know: Tuesday, March 14, 2017
Virginia Lau
March 14, 2017
2:45 pm

Pershing Square sells entire Valeant stake; FDA approves Novartis breast-cancer drug combo; Express Scripts asks Gilead to lower hep-C drug prices

Five things for pharma marketers to know: Thursday, December 29, 2016
Five things for pharma marketers to know: Thursday, December 29, 2016
Jaimy Lee
December 29, 2016
2:55 pm

Gilead forms network to encourage access to hep.-C drugs; Dentsu CEO to resign following the suicide of a staffer; BI to divest animal-health products

Gilead’s Meyers on making deals and finding unmet patient needs
Gilead’s Meyers on making deals and finding unmet patient needs
Virginia Lau
November 29, 2016
3:19 pm

The drugmaker’s new EVP of worldwide commercial operations also talks about tackling medication access, product launches, and starting a commercial team from scratch.

  • From Our Partners